×
About 4,110 results

ALLMedicine™ Vitiligo Center

Research & Reviews  1,430 results

Body dysmorphia in common skin diseases: Results of an observational, cross-sectional m...
https://doi.org/10.1111/bjd.21021
The British Journal of Dermatology; Schut C, Dalgard FJ et. al.

Jan 19th, 2022 - Body dysmorphic disorder (BDD) is a common psychiatric disorder associated with high costs for healthcare systems as patients may repeatedly ask for different, often not effective interventions. BDD symptoms are more prevalent in patients with der...

Biologic and targeted therapeutics in Vitiligo.
https://doi.org/10.1111/jocd.14770
Journal of Cosmetic Dermatology; Karagaiah P, Schwaertz RA et. al.

Jan 15th, 2022 - Vitiligo is a long standing progressive autoimmune disease with depigmented macules/ patches with a significant psychological morbidity to the patients. From being one of the most poorly understood diseases in the past, there has been a rampant ad...

Dupilumab for the Treatment of Actinic Prurigo.
https://www.ncbi.nlm.nih.gov/pubmed/35022123
Skinmed Perz AM, Fawaz B et. al.

Jan 14th, 2022 - A 42-year-old Latino man with a medical history of vitiligo presented to our outpatient clinic with a 25-year history of a recurrent, itchy eruption on his face and hands. Physical examination revealed pink, scaly, erythematous, lichenified papule...

Noncultured Epidermal Suspension in Vitiligo-A Review of Origins, Modifications, and In...
https://www.ncbi.nlm.nih.gov/pubmed/35022112
Skinmed Mhatre M, Sharma A et. al.

Jan 14th, 2022 - Vitiligo, a disorder of depigmentation, has a profound psychosocial burden. Surgical techniques using transplantation of tissue grafts or melanocytes have long been used to correct vitiliginous macules, often utilizing noncultured epidermal suspen...

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patie...
https://doi.org/10.1001/jamadermatol.2021.5476
JAMA Dermatology; Tang K, Seo J et. al.

Jan 13th, 2022 - Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our knowledge, little is known about the predictive value of these cutaneous eruptions an...

see more →

Guidelines  1 results

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.

Aug 7th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  47 results

A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
https://clinicaltrials.gov/ct2/show/NCT03099304

Dec 10th, 2021 - The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.

Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy
https://clinicaltrials.gov/ct2/show/NCT02985151

Nov 22nd, 2021 - In dermatology, the use of Light Amplification by Stimulated Emission of Radiation (laser) has revolutionized the management of various conditions including angiomas, vitiligo, wrinkles, and scars. (Omi, 2014 and Chapas, 2008) Scars result from su...

Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT05121532

Nov 16th, 2021 - This prospective study will include 30 patients with NSV, attending the Outpatient Clinics of Dermatology at Sohag University Hospitals, as well as 30 normal volunteers as control. This study will be submitted for approval by Research and Ethical ...

Evaluation of AMG 714 for Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04338581

Nov 1st, 2021 - The primary objective of this trial is to determine the efficacy of interleukin-15 (IL-15) inhibition with AMG 714 at inducing facial repigmentation in vitiligo. The secondary objectives are to: -Evaluate the safety and tolerability of AMG 714 in ...

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment
https://clinicaltrials.gov/ct2/show/NCT04738149

Oct 21st, 2021 - The purpose of this research is to treat vitiligo with a topical PGF2α, microneedling and excimer laser. The goal is to have greater repigmentation than the standard of care (excimer) after 12 weeks of treatment. The study is a pilot, split study ...

see more →

News  153 results

Increased burden of psychiatric, dermatologic, and systemic comorbidities in adults with atopic dermatitis
https://www.mdedge.com/dermatology/article/250218/atopic-dermatitis/increased-burden-psychiatric-dermatologic-and-systemic

Dec 25th, 2021 - Key clinical point: Atopic dermatitis (AD) was associated with an increased burden of a wide range of psychiatric, dermatologic, and extracutaneous comorbidities, increased awareness of which could help better patient management. Major finding: Co.

Ruxolitinib Cream Meets Primary Endpoints in Phase 3 Vitiligo Trial
https://www.medscape.com/viewarticle/960220

Oct 4th, 2021 - A topical cream formulation of the JAK inhibitor ruxolitinib was superior to its vehicle for treating vitiligo across all primary and secondary endpoints in two multicenter phase 3 trials presented together at the annual meeting of the European Ac...

Explaining Away Those Shades of Gray
https://www.mdedge.com/clinicianreviews/article/245899/dermatology/explaining-away-those-shades-gray
Joe R. Monroe, MPAS, PA

Sep 9th, 2021 - ANSWER The correct answer is that new hairs growing in to replace those lost from alopecia areata tend to be white (choice “b”). They usually regain their normal color, eventually.

Insurance Coverage for Vitiligo Treatment Varies Widely in the US, Analysis Finds
https://www.medscape.com/viewarticle/956472

Aug 12th, 2021 - Health insurance coverage policies for vitiligo treatment lack uniformity and are marked by significant gaps in coverage, which may disproportionately affect patients of color. Those are the conclusions from an analysis of vitiligo treatment cover...

Tebentafusp for Uveal Melanoma: Adverse Events
https://www.onclive.com/view/tebentafusp-for-uveal-melanoma-adverse-events

Aug 2nd, 2021 - Marlana M. Orloff, MD: When I first started introducing the mechanism of tebe [tebentafusp], I mentioned that gp100 [glycoprotein 100] is in 2 places—on the tumor and in the skin on the melanoma site. There was another interesting abstract that ta...

see more →

Patient Education  7 results see all →